Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: An evidence-based interpretation

Rheumatology (United Kingdom)

Volumn 49, Issue 5, 2010, Pages 837-843

  Padol, Ireneusz T ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Anti inflammatory drugs; Anti rheumatic agents; Atheroma; Atherosclerosis; Cardiovascular risk; Gastrointestinal risk; Immunomodulation; Myocardial infarction.; NSAIDs; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID; PROSTAGLANDIN;

ARTIFICIAL EMBOLIZATION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; TH1 CELL; TH2 CELL; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; METABOLISM; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; IMMUNOMODULATION; MYOCARDIAL INFARCTION; OSTEOARTHRITIS; PLAQUE, ATHEROSCLEROTIC; PROSTAGLANDINS; TH1 CELLS;

EID: 77956263936     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep225     Document Type: Review

References (82)

1. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40:1345–50.
2. Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Inest 2006;116:4–15.
3. Smyth EM, Grosser T, Wang M, Yu Y, Fitzgerald GA. Prostanoids in health and disease. J Lipid Res 2009;50: S423–8.
4. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 2006;1:1–10.
5. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005;365:475–81.
6. Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 2006;61:730–7.
7. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27: 1657–63.
8. Hennekens CH, Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther 2008;13:41–50.
9. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302–8.
10. Sorensen R, Abildstrom SZ, Torp-Pedersen C, Gislason GH. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. J Cardiovasc Nurs 2008;23:14–19.
11. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 2008;371: 270–3.
12. Bresalier RS, Friedewald VE Jr, Rakel RE, Roberts WC, Williams GW. The editor’s roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. Am J Cardiol 2005;96: 1589–604.
13. Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y. The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame. J Cardiovasc Pharmacol Ther 2007;12:98–111.
14. Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33–43.
15. Fernandes JL, Mamoni RL, Orford JL et al. Increased Th1 activity in patients with coronary artery disease. Cytokine 2004;26:131–7.
16. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26:2421–32.
17. Mazzolai L, Duchosal MA, Korber M et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 2004;44:277–82.
18. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 2003;21: 303–14.
19. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205: 339–46.
20. Laurat E, Poirier B, Tupin E et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001;104: 197–202.
21. Mallat Z, Tedgui A. Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Exp Opinion Biol Ther 2004;4:1387–93.
22. Caligiuri G, Rudling M, Ollivier V et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Medicine 2003;9:10–17.
23. Potteaux S, Esposito B, van Oostrom O et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004;24: 1474–8.
24. Adler A, Levy Y, Roth A, Wexler D, Keren G, George J. Functional T-lymphocyte dichotomy in the peripheral blood of patients with unstable angina. Int J Cardiovasc Intervent 2005;7:146–51.
25. Paffen E, Medina P, de Visser MC et al. The -589C>T polymorphism in the interleukin-4 gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals. J Throm Haemost 2008;6:1633–8.
26. Pasqui AL, Di Renzo M, Auteri A, Puccetti L. Cytokines in acute coronary syndromes. Int J Cardiol 2005;105:355–6.
27. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005;45:1939–45.
28. Steppich BA, Moog P, Matissek C et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007;190:443–51.
29. Heeneman S, Donners MM, Bai L, Daemen MJ. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity? Exp Rev Cardiovasc Ther 2007;5:345–64.
30. Magen E, Borkow G, Bentwich Z, Mishal J, Scharf S. Can worms defend our hearts? Chronic helminthic infections may attenuate the development of cardiovascular diseases. Med Hypotheses 2005;64:904–9.
31. Wells RW, Blennerhassett MG. The increasing prevalence of Crohn’s disease in industrialized societies: the price of progress? Can J Gastroenterol 2005;19:89–95.
32. Aukrust P, Yndestad A, Smith C et al. Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opin Pharmacother 2005;6:2169–80.
33. Braunersreuther V, Zernecke A, Arnaud C et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007;27:373–9.
34. Ghittoni R, Lazzerini PE, Pasini FL, Baldari CT. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm Allergy Drug Targets 2007;6:3–16.
35. Khallou-Laschet J, Tupin E, Caligiuri G et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 2006;184:330–41.
36. Namiki M, Kawashima S, Yamashita T et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004;172:21–9.
37. Shibata Y, Ohata H, Yamashita M et al. Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette-Guerin (BCG)-treated apolipoprotein E-knockout (apo E-/-) mice. Translat Res: J Lab Clin Med 2007;149:62–9.
38. Damas JK, Smith C, Oie E et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 2007;27:614–20.
39. Shibata Y, Henriksen RA, Honda I, Nakamura RM, Myrvik QN. Splenic PGE2-releasing macrophages regulate Th1 and Th2 immune responses in mice treated with heat-killed BCG. J Leukoc Biol 2005;78:1281–90.
40. Kuroda E, Sugiura T, Zeki K, Yoshida Y, Yamashita U. Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice. J Immunol 2000;164:2386–95.
41. Gold KN, Weyand CM, Goronzy JJ. Modulation of helper T cell function by prostaglandins. Arthritis Rheum 1994;37: 925–33.
42. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993;150:5321–9.
43. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991;146:108–13.
44. Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 2003;170:757–64.
45. Demeure CE, Yang LP, Desjardins C, Raynauld P, Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur J Immunol 1997;27:3526–31.
46. Paliogianni F, Boumpas DT. Prostaglandin E2 inhibits the nuclear transcription of the human interleukin 2, but not the Il-4, gene in human T cells by targeting transcription factors AP-1 and NF-AT. Cellular Immunol 1996;171: 95–101.
47. Katamura K, Shintaku N, Yamauchi Y et al. Prostaglandin E2 at priming of naive CD4þ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995;155:4604–12.
48. McGeer PL, McGeer EG, Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol 2002;37:925–9.
49. Pellicano A, Imeneo M, Leone I, Larussa T, Luzza F. Enhanced activation of cyclooxygenase-2 downregulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa. Helicobacter 2007;12:193–9.
50. Meyer F, Ramanujam KS, Gobert AP, James SP, Wilson KT. Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori. J Immunol 2003;171:3913–17.
51. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which downregulates dendritic cell functions. J Immunol 2002;168: 2255–63.
52. Teloni R, Giannoni F, Rossi P, Nisini R, Gagliardi MC. Interleukin-4 inhibits cyclo-oxygenase-2 expression and prostaglandin E production by human mature dendritic cells. Immunol 2007;120:83–9.
53. Niiro H, Otsuka T, Tanabe T et al. Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4. Blood 1995; 85:3736–45.
54. Roper RL, Brown DM, Phipps RP. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol 1995;154:162–70.
55. Goto T, Herberman RB, Maluish A, Strong DM. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983;130:1350–5.
56. Haas AR, Sun J, Vachani A et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Canc Res 2006;12:214–22.
57. Sharma S, Zhu L, Yang SC et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005;175:813–19.
58. Inoue J, Aramaki Y. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen. J Invest Dermatol 2007;127:614–21.
59. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nature Med 1999;5:900–6.
60. Turull A, Queralt J. Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-mycobacterium antibodies in adjuvant arthritic rats. Immunopharmacol 2000;46:71–7.
61. Muthian G, Raikwar HP, Johnson C et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006;26:73–85.
62. Andreone P, Gramenzi A, Loggi E et al. In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. Cytokine 2004;26:95–101.
63. Perez-Santos JL, Talamas-Rohana P. In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunol 2001;23: 599–606.
64. De Freitas LA, Mbow LM, Estay M, Bleyenberg JA, Titus RG. Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major. Parasite Immunol 1999;21:273–7.
65. Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 1995;7: 372–9.
66. Goodwin JS, Bankhurst AD, Murphy SA, Selinger DS, Messner RP, Williams RC Jr. Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin. J Clin Lab Immunol 1978;1:197–9.
67. Sheibanie AF, Yen JH, Khayrullina T et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23—>IL-17 axis. J Immunol 2007;178: 8138–47.
68. Stamp LK, Cleland LG, James MJ. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J Rheumatol 2004;31:1246–54.
69. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/ interleukin-17 axis. Arthritis Rheum 2007;56:2608–19.
70. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J 2004;18: 1318–20.
71. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 2004;37:71–7.
72. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985;57:65–73.
73. Stein O, Dabach Y, Ben Naim M, Halperin G, Stein Y. Lower macrophage recruitment and atherosclerosis resistance in FVB mice. Atherosclerosis 2006;189:336–41.
74. Padol IT, Hunt RH. Host-specific differences in the physiology of acid secretion related to prostaglandins may play a role in gastric inflammation and injury. Am J Physiol Gastrointest Liver Physiol 2005;288:G1110–17.
75. Kennedy BP, Payette P, Mudgett J et al. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 1995;270:22378–85.
76. Chung HK, Lee IK, Kang H et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002;34:451–61.
77. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983–4.
78. Arnaud C, Veillard NR, Mach F. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:127–34.
79. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.
80. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36–40.
81. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10: 352–6.
82. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95: 1949–54.